SCHEMBL26969856

SCHEMBL26969856

CC1(C)OB(c2ccc3[nH]c(=O)cc(Cl)c3c2)OC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.42
LMNA P02545 1/20 0.41
EGFR P00533 2/20 0.38
PRMT5 O14744 2/20 0.38
WDR77 Q9BQA1 2/20 0.38
LPL P06858 5/20 0.36
LIPG Q9Y5X9 5/20 0.36
CSF1R P07333 1/20 0.36
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35
TP53 P04637 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PDPK1 O15530 1/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA9 Q16790 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
CA12 O43570 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20715158 0.80 LPL (0.46) EGFRPRMT5WDR77LPLLIPG
SCHEMBL29396069 0.80 LPL (0.46) EGFRPRMT5WDR77LPLLIPG
SCHEMBL3260895 0.77 CA9 (0.47) PRMT5WDR77LPLLIPGCSF1R
SCHEMBL20227582 0.77 PRMT5 (0.46) LMNAPRMT5WDR77LPLLIPG
SCHEMBL2098959 0.75 CA9 (0.50) ARLPLLIPGCA1CA2
SCHEMBL20227547 0.75 PARP1 (0.50) LMNAPRMT5WDR77LPLLIPG
SCHEMBL23347163 0.74 LPL (0.43) EGFRPRMT5WDR77LPLLIPG
SCHEMBL29392223 0.74 LPL (0.47) EGFRPRMT5WDR77LPLLIPG
SCHEMBL29490757 0.74 LPL (0.44) PRMT5WDR77LPLLIPGCSF1R
SCHEMBL1542754 0.74 LPL (0.47) EGFRPRMT5WDR77LPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4251617-B1 (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARM SPA (IT) 2025-03-12 EP disclosed
US-20230416233-A1 (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-12-28 US disclosed
EP-4251617-A1 (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2023-10-04 EP disclosed
WO-2022112491-A1 (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416233-A1 (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 AR 2721/4885LMNA 3681/4885EGFR 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.